

**EMBARGOED UNTIL 6:45 AM ET, AUGUST 25, 2021**

**News Release**

**Media Contacts:**

Jake Sargent

+1 (732) 524-1090

[JSargen3@jnj.com](mailto:JSargen3@jnj.com)

Seema Kumar

+1 908-405-1144

[SKumar10@its.jnj.com](mailto:SKumar10@its.jnj.com)

Elisabeth Felice Nehls

+49 172 261-8191

ENehls@its.jnj.com

**Investor Relations:**

Jennifer McIntyre

+1 732-524-3922

**Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine**

*Johnson & Johnson COVID-19 vaccine booster, after single dose primary regimen, provided rapid and robust increase in spike-binding antibodies*

*New studies build on data demonstrating strong durability through eight months after immunization*

**NEW BRUNSWICK, N.J.,** AUGUST 25, 2021 – Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.

In July, the Company [reported](https://www.jnj.com/johnson-johnson-single-shot-covid-19-vaccine-demonstrated-a-durable-immune-response-and-elicited-dual-mechanisms-of-protection-against-delta-and-other-sars-cov-2-variants-of-concern-in-data-published-in-new-england-journal-of-medicine) interim Phase 1/2a data published in the [*New England Journal of Medicine*](https://www.nejm.org/doi/full/10.1056/NEJMc2108829) that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.

In anticipation of the potential need for boosters, the Company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine. New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination. Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose. The study summaries are being submitted to MedRxiv in parallel.

“We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. “We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.”

The Company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA), World Health Organization (WHO) and other health authorities regarding boosting with the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson continues to diligently generate and evaluate data from ongoing trials as well as emerging real-world evidence.

The Phase 1/2a clinical trials (VAC31518COV1001 and VAC3518COV2001) have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under other transaction authority (“OTA”) agreement No. HHSO100201700018C.

For more information on the Company’s multi-pronged approach to helping combat the pandemic, visit: [www.jnj.com/covid-19](http://www.jnj.com/covid-19).

###

**Authorized Use**  
The Janssen COVID-19 vaccine is authorized for use in the U.S. under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

**IMPORTANT SAFETY INFORMATION**

**WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE JANSSEN COVID-19 VACCINE?**  
Tell the vaccination provider about all of your medical conditions, including if you:

* have any allergies
* have a fever
* have a bleeding disorder or are on a blood thinner
* are immunocompromised or are on a medicine that affects your immune system
* are pregnant or plan to become pregnant
* are breastfeeding
* have received another COVID-19 vaccine

**WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE?**  
You should not get the Janssen COVID-19 Vaccine if you:

* had a severe allergic reaction to any ingredient of this vaccine.

**HOW IS THE JANSSEN COVID-19 VACCINE GIVEN?**  
The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle. The Janssen COVID-19 Vaccine vaccination schedule is a **single dose**.

**WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE?**  
Side effects that have been reported with the Janssen COVID-19 Vaccine include:

* Injection site reactions: pain, redness of the skin, and swelling.
* General side effects: headache, feeling very tired, muscle aches, nausea, fever.

Severe Allergic Reactions  
There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Janssen COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

* Difficulty breathing
* Swelling of your face and throat
* A fast heartbeat
* A bad rash all over your body
* Dizziness and weakness

Blood Clots with Low Levels of Platelets  
Blood clots involving blood vessels in the brain, lungs, abdomen, and legs along with low levels of platelets (blood cells that help your body stop bleeding), have occurred in some people who have received the Janssen COVID-19 Vaccine. In people who developed these blood clots and low levels of platelets, symptoms began approximately one to two-weeks following vaccination. Reporting of these blood clots and low levels of platelets has been highest in females ages 18 through 49 years. The chance of having this occur is remote. You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:

* Shortness of breath,
* Chest pain,
* Leg swelling,
* Persistent abdominal pain,
* Severe or persistent headaches or blurred vision,
* Easy bruising or tiny blood spots under the skin beyond the site of the injection.

These may not be all the possible side effects of the Janssen COVID-19 Vaccine. Serious and unexpected effects may occur. The Janssen COVID-19 Vaccine is still being studied in clinical trials.

Guillain Barré Syndrome  
Guillain Barré syndrome (a neurological disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who have received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within 42 days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is very low. You should seek medical attention right away if you develop any of the following symptoms after receiving the Janssen COVID-19 Vaccine:

* Weakness or tingling sensations, especially in the legs or arms, that’s worsening and spreading to other parts of the body
* Difficulty walking
* Difficulty with facial movements, including speaking, chewing, or swallowing
* Double vision or inability to move eyes
* Difficulty with bladder control or bowel function

**WHAT SHOULD I DO ABOUT SIDE EFFECTS?**  
If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

Report vaccine side effects to **FDA/CDC Vaccine Adverse Event Reporting System (VAERS).** The VAERS toll-free number is 1-800-822-7967 or report online to <https://vaers.hhs.gov/reportevent.html>. Please include “Janssen COVID-19 Vaccine EUA” in the first line of box #18 of the report form. In addition, you can report side effects to Janssen Biotech Inc. at 1-800-565-4008.

Please read Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including full EUA Prescribing Information available at [**www.JanssenCOVID19Vaccine.com/EUA-factsheet**](file:///C:\Users\JHuey\AppData\Local\Microsoft\Windows\INetCache\Content.Outlook\ZC6BEDD1\www.JanssenCOVID19Vaccine.com\EUA-factsheet)

**About Johnson & Johnson**  
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at [www.jnj.com](http://www.jnj.com). Follow us at [@JNJNews](http://www.twitter.com/jnjnews).

**About the Janssen Pharmaceutical Companies of Johnson & Johnson**

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at [www.janssen.com](http://www.janssen.com/). Follow us at [@JanssenGlobal](https://twitter.com/JanssenGlobal).

***Cautions Concerning Forward-Looking Statements***

This media statement contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov/), [www.jnj.com](http://www.jnj.com/) or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

###